Facebook
Twitter
LinkedIn
Forward
Harnessing the Power of Telemedicine: Assessing and Treating Psychosis in Neurodegenerative Brain Diseases Remotely (CME/CE Monograph)
Activity Description and Purpose
Millions of adults with chronic illnesses are currently experiencing disruption of access to the quality of care they might normally receive. For patients with degenerative neurologic conditions such as Parkinson’s disease or dementias, new-onset psychosis has a high likelihood of being undetected or undertreated during this time. These same patients are also at high risk of complications of COVID-19, and protecting them in their place of residence is a desirable goal. Telemedicine has quickly emerged as a solution to adapt to practice. Although telemedicine has been a developing area for some time, COVID-19 has rapidly thrust practices and patients into its application. In this 2-part webcast, psychosis in the context of neurodegenerative disease and environmental stressors will be discussed, along with current best practices and clinical pearls in the application of telemedicine to meet the needs of vulnerable patients. The desired results of this educational activity are to provide expert guidance on the use of telemedicine to clinicians caring for older adults with symptoms of psychosis during the COVID-19 outbreak and beyond.
Target Audience
This educational activity is intended for neurologists, psychiatrists, and primary care physicians.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the relationships among comorbid medical, psychosocial, and environmental stressors, neurodegenerative disease, and symptoms of psychosis
- Discuss the rationale for incorporating telemedicine into care for older adults with neurodegenerative disease
- Develop strategies to assess and manage symptoms of psychosis via telemedicine using current best practices
Faculty
George T. Grossberg, MD (Chair)
Samuel W. Fordyce Professor
Director, Geriatric Psychiatry
Department of Psychiatry and Behavioral Neuroscience
Saint Louis University School of Medicine
St Louis, Missouri
Pratap Chand, MD, FRCP
Professor of Neurology
Director, Movement Disorders
Director, Division of General Neurology
Department of Neurology
Saint Louis University School of Medicine
St Louis, Missouri
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Dr Chand has no relevant commercial relationships to disclose.
Dr Grossberg is a contracted researcher for F. Hoffmann-La Roche Ltd and Janssen Global Services, LLC; is a consultant for ACADIA Pharmaceuticals Inc, Alkahest, Inc, Avanir Pharmaceuticals, Inc, Axsome Therapeutics, Inc, Biogen Inc, BioXcel Therapeutics, Genentech, Inc, H. Lundbeck A/S, Karuna Therapeutics, Otsuka America Pharmaceutical, Inc, and Takeda Pharmaceuticals USA, Inc; and receives other funding (Safety Monitoring Committee) from Avanex Corporation, EryDel SPA, and Newron Pharmaceuticals SPA.
Peer Reviewer Disclosure
Rita Khoury, MD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at [email protected].
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or ACADIA Pharmaceuticals Inc.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 225
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation